UK grants approval for Valneva’s chikungunya vaccine

5 February 2025

French biotech Valneva (Nasdaq: VALN) has secured marketing approval in the UK for its chikungunya jab, Ixchiq (chikungunya vaccine), marking the fourth regulatory approval for the world’s first vaccine against the virus.

Chikungunya, which is spread by certain mosquitoes, is a potentially severe virus that can cause lasting joint pain. In many parts of the world it is endemic, with India reporting 370,000 cases since 2019.

The Medicines and Healthcare products Regulatory Agency granted authorization for the vaccine, which is given as a single dose, for people over the age of 18. Valneva has also applied to extend the vaccine’s use to adolescents in multiple markets, including in the UK.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK